CPD Supplements 2020

  • AdobeStock_268793304

    Global regulatory frameworks for the development of gene therapy products

    2020-11-01T15:44:00+00:00By , ,

    Gene therapies have the potential to revolutionise the global healthcare system. Some of these products may offer curative benefits to patients with devastating conditions. This continuing professional development (CPD) supplement provides an overview of the regulatory framework for the development of gene therapy products in key markets.

  • AdobeStock_268793304

    Gene therapy: regional assessment comparison

    2020-11-01T15:52:00+00:00By , ,

    Axicabtagene ciloleucel (tradename YESCARTA) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets CD19 and is approved for the treatment of aggressive, relapsed or refractory forms of B-cell non-Hodgkins lymphoma (NHL). The active substance is composed of a patient’s cells that have undergone ex vivo modification, which causes ...

  • AdobeStock_59790119

    Expedited drug development regulatory pathways in the EU and the US

    2020-10-01T09:54:00+01:00By , Natalie Thomas, , , ,

    This continuing professional development (CPD) supplement focuses on the regulatory framework available to drug developers for expediting their products’ development and review processes in the EU and US. These mechanisms are relevant for products which address an unmet medical need in the treatment of a serious and/or life-threatening condition.

  • AdobeStock_59790119

    The Olaratumab experience

    2022-06-09T10:47:00+01:00By , Natalie Thomas, , , ,

    As highlighted within this CPD article, a conditional marketing authorisation (CMA) can be revoked in Europe. However only one occurrence has occurred since 2006 (in April 2019). Lartruvo (olaratumab), a humanised antibody, was granted a CMA via accelerated assessment on 9 November 2016 for adult patients with a locally advanced, ...

  • AdobeStock_502276195

    Presentation of immunogenicity-related information in regulatory dossiers

    2020-05-01T13:31:00+01:00By Paul Chamberlain

    The purpose of this continuing professional development supplement is to explain how an integrated summary report can be created to consolidate the information required for assessment of immunogenicity-related risks of different types of biopharmaceuticals.

  • AdobeStock_502276195

    Creating an integrated summary of immunogenicity report

    2020-05-01T13:43:00+01:00By Paul Chamberlain

    The purpose of this case study is to illustrate the creation of an integrated summary of immunogenicity report (ISI) that fulfils the recommendations described in current regulatory guidance for the scope of information needed to facilitate assessment of immunogenicity-related risks to support marketing authorisation of novel and biosimilar versions of ...

  • AdobeStock_107034886

    How to manage teams through change

    2020-02-01T14:11:00+00:00By Joe Cheal

    Within this continuing professional development (CPD) article we introduce some practical models and tools that can be actively utilised to the benefit of any manager who is responsible for implementing change.

  • AdobeStock_107034886

    The psychological contract and the hierarchy of criteria

    2020-02-01T14:19:00+00:00By Joe Cheal

    The following exercise will give some insights into people’s immediate reactions to change. This could apply to you or your teams’ reactions: